Does Ozempic Cause Constipation? The Clinical Evidence on GLP-1s and Bowel Function
Does Ozempic Cause Constipation? The Clinical Evidence on GLP-1s and Bowel Function
The Short Answer
- Yes — semaglutide causes meaningful constipation. In the STEP 1 trial of semaglutide 2.4 mg over 68 weeks, constipation occurred in 23.4% of users vs 9.5% on placebo; the 2-year STEP 5 trial pushed that to 30.9% vs 11.2%. [1] [4]
- The mechanism is delayed gastric emptying plus reduced intake. Pooled scintigraphy data show GLP-1 agonists slow gastric emptying half-time by about 36 minutes vs placebo (138.4 min vs 95.0 min), and appetite suppression cuts food and fluid volume — both directly slow stool transit. [3]
- Constipation concentrates during dose escalation and is mostly mild-to-moderate. Across the STEP and SURMOUNT trials, most GI events occurred during the titration phase and resolved as the body adapted, but 4–11% of patients still discontinue treatment because of GI symptoms overall. [1] [6] [7]
- It's not unique to semaglutide. Tirzepatide produced constipation in 11.7–16.8% of SURMOUNT-1 patients (vs 5.8% placebo) and 23.0% in SURMOUNT-3 (vs 6.8%); liraglutide came in at 31.5% in STEP 8. A 2025 Bayesian network meta-analysis found no statistically significant differences between active GLP-1 drugs for constipation specifically. [2] [5] [6] [7]
- Hydration, fiber, movement, and an osmotic laxative resolve most cases. Stop escalating the dose while constipated, target 2.5–3 L fluid and 25–35 g fiber per day, walk after the largest meal, and add polyethylene glycol 3350 (Miralax-class) before reaching for stimulant laxatives.
"How do I get things moving again?" is one of the most common questions on the Ozempic and Mounjaro subreddits. The honest answer from the trials: yes, these drugs really do cause constipation in a meaningful share of people — about 1 in 4 in the weight-loss studies — and the reason is mechanical. The same effect that makes you feel full faster also slows everything else down. Most cases respond to water, fiber, walking, and an osmotic laxative if needed, without stopping the drug.
The clearest numbers come from the STEP 1 trial — nearly 2,000 adults on semaglutide 2.4 mg or placebo for 68 weeks. [1] Constipation was reported by 23.4% of semaglutide users versus 9.5% on placebo — more than double the placebo rate. The 2-year STEP 5 trial pushed that even higher, to 30.9% vs 11.2%. [4] In both trials the constipation was mostly mild to moderate and concentrated in the first few months while the dose was ramping up.
What the numbers actually mean
The rate looks very different depending on which group of patients you ask about. The dedicated weight-loss trials show 23–39% of people getting constipation. A 2025 review of 48 studies in diabetes patients (using lower doses) found just 7.9% across all GLP-1 drugs combined. [2] Both numbers are true — they just describe different doses and different populations. If you're on semaglutide 2.4 mg for weight loss, the higher number is closer to your reality.
average delay in how long your stomach takes to empty on a GLP-1
Pooled data from gold-standard imaging studies show GLP-1 drugs slow stomach emptying from about 95 minutes to about 138 minutes — and the same slowdown continues all the way through your gut. That's why constipation shows up. [3]
The next question people usually ask: is the drug actually causing the constipation, or is it that you're eating and drinking less? Both — and they reinforce each other. The drug directly slows the muscles that push food through your gut — what doctors call peristalsis. [3] On top of that, eating less means less bulk in your colon, and not feeling thirsty means less water for stool to form properly. The two effects stack: less stuff moving through, slower. If you've also dropped your dietary fiber intake along with everything else (which is very common on a GLP-1), that's a third multiplier on top.
Why doesn't everyone get constipated?
Individual gut responses to GLP-1 stimulation vary a lot. Some people get diarrhea instead (semaglutide also has about a 10% diarrhea rate). Some get neither. Baseline diet, hydration habits, fiber intake, activity level, other medications, and personal gut microbiome composition all factor in. The Xie 2025 network meta-analysis found that across the GLP-1 class, constipation rates differ numerically between drugs but the differences weren't statistically significant — meaning there's no "easier-on-the-gut" drug you can switch to that's clearly better for constipation specifically. [2]
The myths to ignore
"If you're constipated, the drug isn't working." It often means the opposite. The same gastric emptying delay that gives you the appetite suppression and weight loss also slows your colon. [3] If you have appetite suppression and weight loss, you also have the receptor activation that's behind the constipation. They're the same effect from your gut's point of view.
"Just stop the drug if you can't go." Across the big weight-loss trials, only 4–11% of people stopped because of any GI side effect at all — most people work through it with the right support. [1] [6] [7] The standard sequence is: stop escalating the dose, push hydration and fiber, walk after meals, and add an osmotic laxative if needed before considering discontinuation.
"Tirzepatide is much gentler on the gut." For constipation specifically, no — the SURMOUNT-1 trial reported tirzepatide constipation in 11.7–16.8% of users vs 5.8% placebo. When tirzepatide was paired with strict diet in SURMOUNT-3, that climbed to 23.0% vs 6.8% — right in the same range as semaglutide. [6] [7] Switching drugs for constipation alone usually isn't worth it.
Your practical protocol
Thirst and appetite go quiet together on a GLP-1, so you can easily drink way less than usual without noticing. Your colon needs water to form normal stool — fiber without water makes constipation worse.
A 500 mL bottle on the nightstand, finished before checking your phone. Refill at every meal. Urine should be pale yellow by mid-afternoon.
Oats, beans, berries, chia, leafy greens. Most adults on a GLP-1 are well under the recommended fiber intake because they're eating less overall. If food alone isn't enough, a psyllium husk supplement (5–10 g daily) works well. Start small and add water; too much fiber too fast can bloat.
Half cup oats + handful of berries (8 g), cup of black beans at lunch (15 g), greens at dinner (3 g) = around 26 g without supplementing.
Walking after eating actually helps your stomach and gut speed up — the opposite of what the drug is doing. It's one of the cheapest and safest interventions you can add.
A loop around the block after dinner is enough. Don't overthink it.
Osmotic laxatives like Miralax pull water into your colon to soften stool. They're considered safe for ongoing daily use and aren't habit-forming. Senna or bisacodyl (stimulant laxatives) work but are best for occasional rescue, not daily use. Same plan whether you're on the weekly injection (Ozempic, Wegovy) or the daily oral pill (Rybelsus).
Typical starting dose: 17 g (one capful) once daily in water. Adjust up or down based on results. If hydration + fiber + walking for 2 weeks hasn't worked, this is your next step.
Every dose increase triggers a new wave of GI symptoms. If you're already constipated at, say, 1.0 mg semaglutide, stay at 1.0 mg an extra month rather than stepping up on the standard schedule. Talk to your prescriber — pausing escalation is a normal, low-friction adjustment.
Same applies to tirzepatide's dose ladder and to Rybelsus oral dose escalation.
What your doctor probably won't go into detail on
Most prescribers will tell you constipation is a possibility and to drink more water — both correct. [1] What usually gets skipped in a 15-minute appointment is the order: pause dose escalation, then hydration plus fiber plus walking, then add Miralax, then re-evaluate. And the reassurance that constipation doesn't mean the drug is hurting you or that you're failing — it means the same effect that's suppressing your appetite is doing what it's designed to do, just everywhere in your gut. [3]
One trap to avoid: making senna or bisacodyl a daily habit. Stimulant laxatives can mess up your normal colon function with long-term daily use — they're meant for occasional rescue, not a maintenance routine. Miralax (or another polyethylene glycol product) is the daily-use maintenance agent for ongoing GLP-1 constipation, and it's considered safe for long-term use.
One thing to get checked: if constipation is severe (no bowel movement in 4–5 days), persistent past month 6 at maintenance dose, or comes with bad belly pain, vomiting, or any sign of bowel blockage — see your doctor, don't manage it from threads. Very rare cases of full bowel obstruction (called ileus) have been reported with both semaglutide and tirzepatide; the absolute risk is small but the consequences are serious enough that it's worth knowing the warning signs.
"How do I get things moving again?" is one of the most common questions on r/Ozempic, r/Semaglutide, and r/Mounjaro after the first few weeks on a GLP-1. The answer the trials give is unambiguous: yes, semaglutide and tirzepatide both cause meaningful constipation — roughly 1 in 4 patients in the largest weight-loss trials — and the mechanism is mechanical (slowed gastric emptying) layered on top of the obvious one (eating and drinking less). Most cases respond to hydration, fiber, and an osmotic laxative if needed, without stopping the drug.
The cleanest constipation incidence data come from the STEP 1 trial: 1,961 adults randomized to semaglutide 2.4 mg or placebo for 68 weeks. [1] Constipation was reported by 23.4% of semaglutide participants versus 9.5% on placebo — an absolute increase of about 14 percentage points, more than doubling the placebo rate. [1] The 2-year STEP 5 trial in 304 patients found an even higher rate of 30.9% with semaglutide vs 11.2% with placebo over 104 weeks, consistent with cumulative exposure. [4] Across both trials, the events were characterized as mostly mild-to-moderate, transient, and concentrated during the dose-escalation phase (weeks 1–16). [1] [4]
What does the research say?
The headline incidence depends heavily on which study population you look at. Dedicated obesity trials with semaglutide 2.4 mg report rates in the 23–39% range; a 2025 Bayesian network meta-analysis of 48 trials in type-2-diabetes patients (n=27,729) pooled the overall incidence across the whole GLP-1 class to just 7.92%. [2] Why the gap? Diabetes trials use lower semaglutide doses (typically 0.5–1.0 mg/week versus 2.4 mg for weight loss), often shorter follow-up, and different baseline patient characteristics. [2] Both numbers are accurate — they answer different questions.
Across the obesity trials, semaglutide 2.4 mg consistently lands in the 23–39% range, while tirzepatide 15 mg lands lower in the standalone trial (11.7%) but climbs to 23.0% when paired with intensive lifestyle intervention. [5] [6] [7] The 2025 Xie network meta-analysis ranked semaglutide as the highest-risk GLP-1 for constipation by SUCRA score (79.5%), with liraglutide #2 (65.1%) and dulaglutide #3, but found no statistically significant differences in constipation rates between any of the active GLP-1 drugs (P>0.05 for all pairwise comparisons). [2] In other words: the rankings are real but the gaps between drugs aren't statistically distinguishable on current data.
average gastric emptying half-time delay on a GLP-1 vs placebo
Pooled scintigraphy data from a 2024 systematic review put gastric emptying T1/2 at 138.4 min on a GLP-1 vs 95.0 min on placebo (p<0.01). Slowing the front end of the GI tract is the upstream cause of the slow-stool problem at the back end. [3]
Why does slow gastric emptying cause constipation downstream?
Three reinforcing mechanisms. First, GLP-1 receptor activation reduces peristalsis in the stomach and proximal small intestine, which delays passage of material into the colon — measured in pooled scintigraphy data as a +36-minute increase in gastric emptying half-time (138.4 min vs 95.0 min on placebo, p<0.01). [3] Second, the appetite-suppression effect cuts food volume and — crucially — fluid intake, so the colon receives less bulk and less water for stool formation. Third, lower total food intake means proportionally less dietary fiber reaches the colon, removing the substrate that drives normal stool bulk and microbial fermentation. The Hiramoto pooled analysis specifically noted that the gastric emptying delay was more pronounced with short-acting GLP-1 agents on scintigraphy (189.6 min vs 127.0 min for long-acting), though the comparison did not reach statistical significance (p=0.076). [3]
Does the constipation get worse with longer treatment?
Cumulative incidence rises with exposure time, but per-month rates tend to fall. STEP 1 reported 23.4% constipation over 68 weeks; STEP 5 reported 30.9% over 104 weeks in the same drug at the same dose. [1] [4] The 7.5-percentage-point gap over the extra 36 weeks is roughly what you'd expect if new cases keep accumulating but at a slower per-month pace than during the titration phase. STEP 5 explicitly characterized GI events as concentrated in the dose-escalation period (weeks 1–16) and noted that events-per-100-patient-years were 230.7 for semaglutide vs 94.1 for placebo — about 2.5× — but driven by the early time window. [4] Practically: most people who develop constipation will develop it in the first 4 months. If you've made it past month 6 without it, your odds of getting it later drop substantially.
The 2025 network meta-analysis ranked semaglutide as the highest-risk GLP-1 for constipation, but found no statistically significant differences between any of the active drugs — the rankings are real but the gaps aren't.
Where does community wisdom diverge from research?
Myth 1: "If you're constipated, the drug isn't working"
It often means the opposite — the drug is working. The same gastric emptying delay that produces the early-satiety sensation and the appetite suppression also slows downstream transit. [3] If you have meaningful appetite suppression and meaningful weight loss, you are by definition getting the receptor activation that also causes the constipation. The corollary: dose reduction will reduce constipation, but it will also reduce the appetite and weight-loss effects proportionally — a trade-off worth discussing with your prescriber before you reach for a dose change.
Myth 2: "Just stop the drug if you can't go"
Almost never the right first move. Across the major obesity trials, GI-event-related discontinuation ran 4–11%: STEP 1 at 4.5%, STEP 5 at 3.9%, SURMOUNT-1 at 4.3–7.1% across dose arms, SURMOUNT-3 at 10.5%. [1] [4] [6] [7] Most people work through it. The standard sequence is: pause dose escalation rather than continuing to step up while constipated, max out hydration and fiber and walking, add an osmotic laxative (polyethylene glycol 3350 / Miralax-class) if needed, and only revisit discontinuation if all of that fails or if red flags appear.
Myth 3: "Tirzepatide is much easier on the gut than semaglutide"
For nausea and vomiting the data on tirzepatide are mixed; for constipation specifically, no — the SURMOUNT-1 trial reported tirzepatide-related constipation in 16.8% (5 mg), 17.1% (10 mg), and 11.7% (15 mg) versus 5.8% placebo — clearly above placebo, just somewhat below semaglutide's 23.4% in STEP 1. [6] When tirzepatide was paired with intensive lifestyle intervention in SURMOUNT-3, constipation rose to 23.0% vs 6.8% placebo, matching the semaglutide range. [7] The Xie 2025 network meta-analysis reported a tirzepatide constipation incidence of 0.14%, but flagged that as based on a single trial and unreliable. [2] Treat the SURMOUNT data as the better guide.
Practical protocol
Reduced thirst and reduced appetite often arrive together on a GLP-1, so you can drift well below baseline fluid intake without noticing. The colon needs water to form normal stool; if you're under-hydrated, fiber alone will make constipation worse, not better.
Concrete habit: a full 500 mL bottle on the nightstand finished before you check your phone in the morning; refill at every meal. If your urine isn't pale yellow by mid-afternoon, you're behind.
Soluble fiber sources (oats, beans, lentils, berries, chia, psyllium) form a gel that helps stool transit; insoluble fiber (whole grains, vegetable skins, nuts) adds bulk. The recommended adult intake is 25 g for women and 38 g for men; most adults on a GLP-1 are eating well under that because total food volume is down. If hitting it from food alone is unrealistic on a suppressed appetite, a daily psyllium husk (5–10 g) is the standard supplement — start low and increase gradually with extra water to avoid bloating.
Practical: a 1/2 cup of oats at breakfast (4 g), a cup of black beans at lunch (15 g), a handful of berries + chia (5 g), and a serving of leafy greens at dinner (3 g) puts you around 27 g without supplementing.
Post-prandial walking enhances gastric emptying and intestinal motility — the opposite of what the drug is doing — and is one of the cheapest, safest interventions you can add. The effect is most pronounced if the walk starts within 30 minutes of eating.
A loop around the block after dinner is enough. Don't overthink it. Resistance training and zone-2 cardio also help, but the after-meal walk is the most specific anti-constipation move.
Osmotic laxatives pull water into the colon and are generally considered safe for ongoing daily use — not habit-forming, not associated with the dependency concerns that come with chronic stimulant use. Typical starting dose is 17 g (one capful) once daily mixed in a glass of water; adjust up or down based on response. Stimulant laxatives (senna, bisacodyl) work but are best used for short-term rescue, not as a daily standby.
If you've been doing hydration plus fiber plus walking for two weeks with no improvement, polyethylene glycol is the next step — not a sign of failure. Magnesium citrate or oxide is an alternative for people who don't tolerate PEG.
The standard semaglutide titration is 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks. If you hit constipation at, say, 1.0 mg, stay at 1.0 for an extra 4 weeks rather than stepping up on schedule. Same logic for tirzepatide's 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg ladder. Every dose escalation re-triggers the worst window of GI symptoms; if you're already symptomatic, escalating now is the wrong move. This is just as true on the daily oral pill (Rybelsus 3 → 7 → 14 → 25 mg) as on the weekly injection.
Talk to your prescriber before holding a dose — but in practice this is a routine, low-friction adjustment in most clinics.
What would your doctor tell you?
Most prescribers cover the constipation risk in the initial visit and write a generic "drink more water, eat more fiber" handout — both correct, both true, both light on specifics. [1] What gets lost in a 15-minute follow-up is the actual sequence (pause escalation → hydration + fiber + walking → osmotic laxative → reassess), the dose-titration leverage point, and the reassurance that constipation does not mean the drug is dangerous or that you're failing the treatment — it means the receptor activation is working as designed. [3]
Dose-day eating. Same protocol whether you're on the weekly injection (Ozempic, Wegovy) or the daily oral pill (Rybelsus). Rybelsus has its own constraint — empty stomach, 30-minute wait before food, drinks (other than 4 oz water), or other meds — and the PIONEER PLUS trial of oral semaglutide 25–50 mg reported constipation in 6–7% of users vs 7% on the lower 14 mg dose, in the same general range as the lower-dose injectable but well under the 2.4 mg obesity doses. [8] The fluid timing is harder on the oral than the injectable because you've also constrained when you can drink in the morning; plan your daily hydration around the morning gap accordingly.
One trap to avoid. Reaching for daily senna or bisacodyl as a permanent fix. Stimulant laxatives can cause habituation and worsen baseline colon function with prolonged daily use — they are short-term rescue, not maintenance. Polyethylene glycol is the maintenance agent for ongoing GLP-1-related constipation. The clinical pharmacokinetics review of semaglutide notes the drug has a roughly 1-week half-life via fatty-acid acylation, so the GLP-1 effect (including on motility) is essentially continuous once you're at steady state — meaning constipation management has to be continuous too, not episodic. [9]
One diagnostic to request. If constipation is severe (no bowel movement for 4–5 days despite the full management protocol), persistent (still daily after the maintenance dose has been stable for 8–12 weeks), or accompanied by red flags (severe abdominal pain, persistent vomiting, blood in stool, signs of bowel obstruction), get evaluated — don't manage it from a Reddit thread. The major obesity trials reported very rare cases of ileus with both semaglutide and tirzepatide; the absolute risk is small but the consequences are severe. Your prescriber should also screen for other contributors — iron supplements, opioids, calcium-channel blockers, low thyroid — that may be stacking with the GLP-1 effect.
Get the GLP-1 Guide for This Topic
Our research-backed guide covering key findings, practical strategies, and evidence-based recommendations from the studies cited in this article.
Free PDF · No spam · Unsubscribe anytime
Clinical citations
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine. 2021;384(11):989–1002. PubMed
- Xie X, Yang S, Deng S, Liu Y, Xu Z, He B. "Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis." Frontiers in Pharmacology. 2025;16:1613610. Full text
- Hiramoto B, Flanagan R, Muftah M, et al. "Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis." American Journal of Gastroenterology. 2024;119(6):1110–1120. Full text
- Garvey WT, Batterham RL, Bhatta M, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nature Medicine. 2022;28(10):2083–2091. PubMed
- Rubino DM, Greenway FL, Khalid U, et al. "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial." JAMA. 2022;327(2):138–150. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine. 2022;387(3):205–216. PubMed
- Wadden TA, Chao AM, Machineni S, et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial." Nature Medicine. 2023;29(11):2909–2918. PubMed
- Aroda VR, Aberle J, Bardtrum L, et al. "Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial." The Lancet. 2023;402(10403):693–704. PubMed
- Yang X-D, Yang Y-Y. "Clinical Pharmacokinetics of Semaglutide: A Systematic Review." Drug Design, Development and Therapy. 2024;18:2555–2570. Full text
Get the GLP-1 Guide for This Topic
Key findings, practical strategies, and evidence-based recommendations — backed by the clinical studies cited above. Free PDF, straight to your inbox.
Free PDF · No spam · Unsubscribe anytime
Medical disclaimer
MetaBa content is educational and does not replace medical advice, diagnosis, or treatment from a licensed clinician. Always consult with your healthcare provider before making changes to your diet, exercise, or medication regimen.
Methodology: Community insights synthesized from 2,100+ posts across r/Ozempic, r/Mounjaro, r/Zepbound, r/GLP1, and r/semaglutide. Clinical claims cite peer-reviewed research with linked sources. Reddit quotes paraphrased and anonymized per platform terms.
